Zero chance of completed trial results. Unlikely also, but maybe they will announce full enrollment in the mild/moderate trials, which would mean we could hear some results in 3 weeks or so. There's a (very) long-shot chance that the FDA says, "Wow! The results from the half-enrolled trial look so darn good, we are calling it off early."

It would be prudent to stake your hopes on something else.

Data-wise?
EUA or close to full enrollment or some nicely organized eIND results (so far they have been haphazard). I actually expect something along those lines because Dr Jay will be there, but not Mulholland or Patterson.

Finance-wise?
A distinct possibility would be gov't funding, which would be a godsend, even if it comes with strings attached (as long as they are not too onerous of strings!).

NP has telegraphed the possibility of a final dilution to raise $$ to get us through the next couple months. I keep hoping the shoestring cobbling together of $$ can get us over the hump, but it may not be possible.

Don't expect an announcement about uplisting. I would guess that won't happen for at least a month, after trials are done and there is a more reasonable guarantee of revenue.